Streetbeat News

FIXX

Homology Medicines Inc

https://www.homologymedicines.com/

CEO

Arthur Tzianabos

Employees

131

Industry

Pharmaceutical Preparation Manufacturing

homology medicines is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.

Open

0.92

Mkt cap

Volume

401K

High

0.97

P/E Ratio

-0.03

52-wk high

26.64

Low

0.90

Div yield

N/A

52-wk low

0.90

Trading for FIXX was halted at 7:50:00 p.m. ET due to pending news. The halt is a temporary measure until the news affecting the company is released.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 11:50 pm

Homology Medicines, Inc. (NASDAQ:FIXX) received a notification from Nasdaq for not meeting the minimum bid price requirement of $1.00 per share for the last 30 business days. The company has until June 26, 2024, to regain compliance. Homology plans to propose a reverse stock split to address this issue ahead of a merger with Q32 Bio Inc. If compliance is not achieved, Homology may face delisting from Nasdaq.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 9:12 pm

In Monday's after-market session, several healthcare stocks experienced significant movements. NGM Biopharmaceuticals, Cue Health, Homology Medicines, Cue Biopharma, Cadrenal Therapeutics, and Biophytis saw their shares rise, with NGM leading the gainers. Conversely, Corcept Therapeutics, China SXT Pharmaceuticals, LumiraDx, Aditxt, Fresh2 Group, and Qilian Intl Hldg Gr faced declines, with Corcept Therapeutics experiencing the largest drop.

Portfolio Pulse from Benzinga Insights

January 01, 2024 | 9:30 pm

U.S. stocks traded lower with the Dow Jones falling over 100 points. Utilities shares surged by 1%, while energy shares fell by 2.2%. Williams-Sonoma (NYSE:WSM) reported better-than-expected Q3 adjusted earnings, beating EPS estimates but falling short on sales expectations. Sonos (NASDAQ:SONO) shares rose 18% after strong Q4 results. WaveDancer (NASDAQ:WAVD) shares jumped 68% due to a merger agreement with Firefly Neuroscience. Universal Technical Institute (NYSE:UTI) gained 14% following strong sales. Volcon (NASDAQ:VLCN) plunged 64% after announcing a public offering. The Children's Place (NASDAQ:PLCE) dropped 29% after weak earnings. Homology Medicines (NASDAQ:FIXX) fell 38% after announcing a merger with Q32 Bio. Gold prices increased by 1.2%, and oil prices declined by 5.7%.

Portfolio Pulse from Lisa Levin

November 16, 2023 | 7:30 pm

The Children's Place, Inc. (NASDAQ:PLCE) shares dropped by approximately 25% due to weaker than expected quarterly earnings, with adjusted earnings of $3.22 per share compared to estimates of $3.56 per share. Despite sales exceeding estimates, the stock price fell significantly. Other stocks experienced movements in Thursday's mid-day session, with various companies reporting earnings, clinical trial updates, mergers, and public offerings.

Portfolio Pulse from Lisa Levin

November 16, 2023 | 6:11 pm

Health care stocks experienced significant movement in Thursday's intraday session. LumiraDx (LMDX) saw a 42.8% increase, while Homology Medicines (FIXX) dropped 39.9%. Other notable gainers include Bone Biologics (BBLG), Impel Pharmaceuticals (IMPL), Iterum Therapeutics (ITRM), Apyx Medical (APYX), and Dermata Therapeutics (DRMA). On the losing side, MEI Pharma (MEIP), Augmedix (AUGX), SAB Biotherapeutics (SABS), PaxMedica (PXMD), and Syra Health (SYRA) saw declines. Volume spikes suggest increased investor interest, potentially due to recent Q3 earnings reports.

Portfolio Pulse from Benzinga Insights

November 16, 2023 | 5:31 pm

U.S. stocks traded lower, with the Dow Jones down 0.40%, NASDAQ down 0.35%, and S&P 500 down 0.23%. Walmart's shares fell 7% post Q3 results, despite beating sales and EPS estimates, as it raised FY24 EPS guidance slightly below the estimate. Crude oil prices dropped 4.3%, while utilities shares surged by 1%. Other notable movements included Sonos up 17% after strong Q4 results, WaveDancer up 60% following a merger agreement, and Dermata Therapeutics up 22% after an FDA agreement. Conversely, Volcon plunged 68% due to a public offering, The Children's Place fell 26% after weak earnings, and Homology Medicines dropped 38% after announcing a stock transaction merger.

Portfolio Pulse from Lisa Levin

November 16, 2023 | 5:02 pm

Homology Medicines Inc (NASDAQ:FIXX) stock is trading lower after announcing a definitive merger agreement with Q32 Bio Inc. The all-stock transaction will result in Q32 Bio becoming a wholly owned subsidiary of Homology Medicines, with the combined company operating under the name Q32 Bio and expected to trade under the ticker 'QTTB'. Pre-merger Homology stockholders will own about 25% of the new entity, while Q32 Bio stockholders will own approximately 75%. Homology Medicines has also discontinued its R&D programs and is exploring strategic alternatives for its technology. The combined company is expected to have a cash balance of $115 million, providing a runway to mid-2026. FIXX shares have dropped 42.82% to $0.5031.

Portfolio Pulse from Vandana Singh

November 16, 2023 | 4:11 pm

Q32 Bio and Homology Medicines have agreed to merge in an all-stock transaction, with the combined entity to focus on Q32 Bio's autoimmune and inflammatory disease candidates. Post-merger, the company will be named Q32 Bio, based in Waltham, Massachusetts, and will trade on Nasdaq under the ticker 'QTTB'.

Portfolio Pulse from Benzinga Newsdesk

November 16, 2023 | 12:07 pm

Healthcare stocks experienced significant movement during Wednesday's intraday session. Heron Therapeutics, Kinnate Biopharma, Mira Pharmaceuticals, Cormedix, Gossamer Bio, and Evelo Biosciences saw their stocks rise following recent earnings reports. Conversely, Aytu BioPharma, Tivic Health Systems, BioCardia, TransCode Therapeutics, Homology Medicines, and Intensity Therapeutics experienced declines in their stock prices, also in the context of recent earnings releases.

Portfolio Pulse from Benzinga Insights

November 15, 2023 | 5:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.